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A B S T R A C T
Gaucher Disease (GD) type 3 is a neurological form of a multisystemic autosomal recessive disorder belonging to
the group of lysosomal storage diseases. Causal mutations in the glucocerebrosidase 1 (GBA1) commonly lead to
abnormal protein and GD, heterozygosity is a genetic risk factor for Parkinson's disease. This work describes the
use of a non-integrative approach using Sendai Virus delivery to establish induced Pluripotent Stem Cells (iPSCs)
from fibroblasts from a GD type 3 patient. Differentiation of iPSCs can be employed to generate a variety of
complex cell types with a high degree of genetic complexity that would otherwise be unattainable.
Resource table
Unique stem cell line i-
dentifier
INSAi001-A
Alternative name(s) of
stem cell line
GD3-1
Institution INSA
Contact information of
distributor
Olga Amaral
Type of cell line Induced pluripotent stem cell line (iPSC)
Origin Human (Istituto "Giannina Gaslini" Biobank)
Additional origin info Age: 27 years
Sex: male
Ethnicity if known: unknown
Cell Source Skin fibroblasts
Clonality Clonal
Method of reprogram-
ming
CytoTune™-iPS 2.0 Sendai
Reprogramming Kit
Genetic Modification Yes
Type of Modification Familial
Associated disease Gaucher Disease
Gene/locus GBA1 gene (Gene ID: 2629)/locus 1q22; Mutations in
compound heterozygosity: p.L444P (rs421016) and
p.F213I (rs381737)
Method of modification Not applicable
Name of transgene or r-
esistance
Not applicable
Inducible/constitutive s-
ystem
Not applicable
Date archived/stock da-
te
2019/06/25
Cell line repository/ba-
nk
The cell line has not been deposited in a stem cell bank or
repository but is physically cryopreserved at INSA's facil-
ities in CSPGF in Porto, Portugal.
Ethical approval Original fibroblast line was obtained from a non-com-
mercial provider, Gaslini Institute Biobank under Genetic
Biobank Guidelines, Telethon - SIGU, Analysis 4/5, 2003.
Italian Data Protection Authority (Garante Privacy),
General Authorisation for the processing of genetic data
no. 8/2016.
1. Resource utility
Lysosomal Storage Diseases (LSDs) may affect hard to reach cells,
such as cardiac cells and neurons, which require invasive procedures to
access the disease-target-tissue. The present work constitutes a first
stage towards the final goal of differentiating iPSCs to generate specific
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cell types to aid model pathogenesis and testing of potential ther-
apeutics. It represents a useful tool for optimization of therapeutic
protocols and identification of key factors regulating pathways in organ
involvement.
2. Resource details
This work focuses on the development of iPSCs from fibroblasts
using non-integrative approaches in a cell line of one of the most
common sphingolipidoses, Gaucher disease (GD). GD is a LSD usually
caused by mutations in the glucocerebrosidase 1 (GBA1, gene ID:2629),
which lead to defective glucocerebrosidase (GlcCerase, EC 3.2.1.45).
Clinically, GD encompasses a continuum of clinical findings with mul-
tisystemic involvement, which for diagnosis purposes is divided in three
main categories. This work used type 3 GD fibroblasts (ORPHA:77,261,
OMIM:231,000). GD type 3, with late onset neurological involvement,
shares clinical features of type 1 and type 2. Over the years, genetic
analyses of Parkinson Disease (PD) patients have demonstrated that
GBA1 missense mutations constitute a relatively common risk factor for
developing PD. The continuum of clinical symptoms of GD now en-
compasses a wide variety of neurologic symptoms in addition to the
multisystemic features.
The original manuscript regarding this cell line had a concomitant
report of two patients with similar GBA1 genotypes but different clin-
ical forms. In such cases, it is particularly difficult to evaluate how
modifying factors can contribute to the different clinical disease ex-
pression. The patient whose cells were used for generating INSAi001-A
was classified as type 3, while a younger patient, with similar genotype,
was type 1 [Filocamo et al., 2002]. Such divergences in symptoms and
classifications make the use of iPSCs particular interesting for model-
ling and pathogenesis studies. As stated in the original paper, the type 3
patient was diagnosed at age five and splenectomyzed at age ten, re-
gardless of enzyme therapy he later developed untreatable epilepsy
[Filocamo et al., 2002]. Interestingly, both mutations exist as pseudo-
gene sequence and they both exist in patients of Japanese origin Ida
et al., 1997.
Differentiation of iPSCs, INSAi001-A, can generate a variety of
complex cell types with a high degree of genetic complexity that would
otherwise be unattainable and might help understand the pathogenesis
of GD in such cases. An iPS cell line, INSAi001-A, was successfully
generated from skin fibroblasts from a compound heterozygous patient.
All results are summarized in Fig. 1. The fibroblasts were repro-
grammed by co-expressing Yamanaka's factors, OCT3/4, SOX2, KLF4,
and cMYC through the integration-free Sendai virus gene-delivery
method on a feeder-free system with vitronectin (Fig. 1A). The
INSAi001-A cell line, showed endogenous expression of the plur-
ipotency markers by positive immunofluorescence staining for NANOG,
SOX2, OCT4 and TRA-1–60 (Fig. 1B1-4) further quantitative analysis
also showed elevated OCT4 by RT-qPCR (Fig. 1C). The resulting iPSCs
INSAi001-A had a normal karyotype (Fig. 1D) and retained the GD-
causing GBA1 mutations (Fig. 1E). Differentiation potential can be seen
in Fig. 1F where formation potential of the three germ layers is shown
by positive Immunofluorescence staining for mesoderm (Brachyury),
endoderm (SOX17) and ectoderm (Otx2). The use of Sendai Virus (SeV)
vectors under feeder free conditions proved to be effective in producing
iPSCs that maintain the original genetic characteristics of the donor
fibroblasts, as far as the extent of the examination as shown by the
causal mutations, gene and STR analysis.
3. Materials and methods
3.1. Biological sample
The skin fibroblast cell line from GD-3 patient was obtained from
Instituto Giannina Gaslini Bioresource Bank in Geneva, Italy in com-
pliance with the ethical recommendations issued by the Oviedo
agreement of 1997 and the International Declaration on Human Genetic
Data of 2003 Filocamo et al., 2014. The GD cell line used was from a
type 3 patient who bears a compound heterozygous genotype with
p.L444P (rs421016) and p.F213I (rs381737).
3.2. Fibroblast culture
Cells were maintained in DMEM(1x) + GlutaMAX™ medium
(Gibco™) supplemented with 10% foetal bovine serum in a cell in-
cubator.
3.3. Reprogramming of fibroblasts to iPSCs
Cellular reprograming of fibroblasts to iPSCs was carried out using a
non-integrative approach. SeV reprogramming was carried out suc-
cessfully on skin fibroblasts using CytoTune™-iPS 2.0 Sendai
Reprogramming Kit (Invitrogen™). As reprogramming matrix
Vitronectin (VTNeN from Gibco™) was used. By the 10th passage SeV
was no longer detected by PCR indicating that the experiment had been
successful and the iPSCs were free of viral footprint. Characterisation
and validation is shown in Fig. 1 and Table 1.
3.4. Cell culture and passage
Cells were cultured on 60 mm plates coated with 1/100 Vitronectin
(VTNeN) Recombinant Human Protein Truncated diluted in 1X DPBS.
Incubation was at 37°C with 5% CO2 in a Refurbished Binder CB 150
Air-Jacketed CO2 Incubator. Once high confluency is reached, the
medium is removed, cells are washed with 1 mL of 1X DPBS and treated
with 1 mL of 0,5 mM EDTA solution, after 4 min of incubation at room
temperature, EDTA is removed. Cell passage is carried out by re-
suspension in Gibco™ StemFlex™ Medium with 1% Lonza
BioWhittaker™ PEN-STREP 5000 U Penicilin/mL and 10% Gibco™
StemFlex™ Suplement (10X); 50 µL of cell suspension are added to new
matrix treated dishes in a 2 mL volume of medium.
3.5. Pluripotency characterisation
As determined by real-time quantitative analysis (Fig. 1C), expres-
sion of the pluripotency gene OCT4 was upregulated in iPSCs compared
to the patient fibroblasts. As seen in Fig. 1B.1–4 qualitative analysis by
immunofluorescence with NANOG, SOX2, OCT4 and TRA-1–60 anti-
bodies (indicated in Table 2), showed positive staining for all plur-
ipotency markers confirming pluripotent status.
3.6. Genetic characterisation
Genotype was established in fibroblasts and in iPSCs and the mu-
tations confirmed (Fig. 1E). See Table 2 for primers used. PCR products
were purified with ExoSAP™-IT (Applied Biosystems™), for Sanger se-
quencing BigDye®Terminator v3.1 (Applied Biosystems™) was used.
STR analysis used the AmpFeSTR® Identifier® (Applied Biosystems™).
Karyotyping was performed on G-banded metaphase chromosomes
using standard procedures and at least five metaphases were examined
per sample. As seen in Fig. 1D, the Karyotype was normal (46, XY).
Quantitative real time polymerase chain reaction (qRT-PCR) was car-
ried out on RNA isolated using TRIzol Reagent (Ambion®). 0.5 μg RNA/
reaction was reverse transcribed using qScript cDNA supermix (Quanta
BIO). Real Time RT-PCR was performed using TaqMan™ Universal PCR
mastermix (Applied Biosystems™). CT-values were normalized to the
housekeeping gene GAPDH using the ΔΔCT-method. Primers are listed
in Table 2.
3.7. Fluorescent immunocytochemistry
To confirm true pluripotency capability of the derived iPSCs, a three
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germ layer test was conducted using Human Pluripotent Stem Cell
Functional Identification Kit (R&D Systems®), to differentiate into en-
doderm and ectoderm. To differentiate into mesoderm, a WNT pathway
activator, CHIR99021 supplement (Stemcell™ Technologies) was used.
The Base Media Supplement (50X) from the Stem Cell Functional
Identification Kit (R&D Systems®) was used in all cases. The Stem Cell
Fig. 1. Characterisation of induced pluripotent stem cell line (INSAi001-A) from A Gaucher type 3 patient.
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Functional Identification Kit (R&D Systems®) also contained antibodies,
against Otx2, Brachyury and SOX17 (ectoderm, mesoderm and en-
doderm markers, respectively). In brief, seeded iPSCs were fixed in 4%
paraformaldehyde (Sigma-Aldrich) for 20 min and washed with PBS.
Subsequently, cells were permeabilized with 0.25% triton X-100
(Sigma-Aldrich) for 10 min, incubated with PBST with 1% BSA (Sigma-
Aldrich) for 30 min and stained by standard immunofluorescence pro-
cedures. Cells were analysed on DM4000 M fluorescence microscope
(Leica). Antibodies are listed in Table 2.
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Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography (clear field microscopy) Visual inspection was normal Fig. 1 panel A
Phenotype Qualitative analysis (Immunofluorescence) Positive for NANOG, SOX2, OCT4 and TRA–1–60 (with DAPI) Fig. 1 panel B
Quantitative analysis (RT-qPCR) Expression of OCT4 Fig. 1 panel C
Genotype Karyotype (G-banding) and resolution 46XY, Resolution 450–500 Fig. 1 panel D
Identity STR analysis DNA Profiling Performed Supplementary file
Mutation analysis Sequencing Compound heterozygous: p.L444P (rs421016) and p.F213I
(rs381737)
Fig. 1 panel E
Microbiology and
virology
PanRac AppliChem PCR Mycoplasma Test Kit
(A3744)
Mycoplasma testing: Negative Not shown but available with
author
Differentiation potential Directed differentiation (Immunofluorescence) and
embryoid body formation
Formation of three germ layers: positive for Otx2 (ectoderm
marker), Brachyury (mesoderm marker), and SOX17
(endoderm marker)
Fig. 1 panel F
Table 2
Reagent details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Mouse anti-Nanog, clone 7F7.1, Alexa Fluor® 488 conjugate 1:100 Millipore Cat# MABD24, RRID:AB_11,203,826
Mouse anti-Sox-2, clone 10H9.1, Cy3 conjugate 1:100 Millipore Cat# MAB4423, RRID:AB_11,205,572
Mouse anti-Oct-4 (POU5f1), clone 7F9.2, Alexa Fluor® 488
conjugate
1:100 Millipore Cat# MAB4419, RRID:AB_1,977,399
Mouse anti-TRA–1–60, clone TRA–1–60, Cy3 conjugate 1:100 Millipore Cat# MAB4360, RRID:AB_2,119,183
Germ layer markers Goat Anti-Human Brachyury Polyclonal Antibody, unconjugated
(Mesoderm)
1:10 R and D Systems Cat# AF2085, RRID:AB_2,200,235
Goat Anti-Human Sox17 Polyclonal Antibody, unconjugated
(Endoderm)
1:10 R and D Systems Cat# AF1924, RRID:AB_355,060
Goat Anti-Human Otx2 Polyclonal Antibody, unconjugated
(Ectoderm)
1:10 R and D Systems Cat# AF1979, RRID:AB_2,157,172
Secondary antibodies Donkey anti-Goat IgG (H+ +L) Cross-Adsorbed Secondary
Antibody, Alexa Fluor 488
1:200 Thermo Fisher Scientific Cat# A-11,055,
RRID:AB_2,534,102
Primers
Target TaqMan® assay
Pluripotency marker (qPCR) OCT-4 hs00999632_g1
House-keeping gene (qPCR) GAPDH hs02786624_g1
Target Forward/Reverse primer 5′–3′
Targeted mutation sequencing Long Range GBA CGACTTTACAAACCTCCCTG/CCAGATCCTATCTGTGCTGG
Nested GBA exon 6 CTAATGGCTGAACCGGATG/GGAAGTGGAACTAGGTTGAGG
Nested GBA exon 10–11 GTGGGTGACTTCTTAGATGAGG/CTTTAGTCACAGACAGCGTGTG
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